Osimertinib As Second- and ≥Third-Line Treatment in Advanced and Recurrence EGFR-Mutant NSCLC Patients Harboring Acquired T790M Mutation

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2025 Jan 8

PMID 39766072

Authors

Mu-Han Peng

Yen-Hsiang Huang

Kuo-Hsuan Hsu

Jeng-Sen Tseng

Po-Hsin Lee

Kun-Chieh Chen

Gee-Chen Chang

Tsung-Ying Yang

Affiliations

Soon will be listed here.

Abstract

Background/objectives: Osimertinib is a standard sequential therapy for advanced and recurrent Epidermal Growth Factor Receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) patients with the T790M mutation, following treatment with first- or second-generation EGFR Tyrosine Kinase Inhibitors (TKIs). This study aims to investigate the differences in clinical outcomes between osimertinib as a 2nd-line treatment and as a ≥3rd-line treatment in this patient population.

Methods: Between September 2014 and March 2023, we enrolled advanced and recurrent T790M + NSCLC patients who had received osimertinib as sequential treatment for analysis. All patients had previously been treated with gefitinib, erlotinib, or afatinib as first-line therapy.

Results: A total of 158 patients who received osimertinib as sequential treatment were included in the final analysis. Of these, 99 patients (62.7%) received osimertinib as a 2nd-line treatment, while 59 patients (37.3%) were treated with osimertinib as ≥3rd-line therapy. The median progression-free survival (PFS) was 10.7 months for the 2nd-line group and 8.9 months for the ≥3rd-line group. The median overall survival (OS) from first-line treatment was 73.2 months in the 2nd-line group and 57.5 months in the ≥3rd-line group. No statistically significant differences in PFS or OS were observed between the two groups.

Conclusions: Our research demonstrated that osimertinib is effective not only as a 2nd-line therapy but also as a ≥3rd-line treatment, offering promising clinical benefits for advanced and recurrent EGFR-mutant NSCLC patients with acquired T790M mutations who have developed resistance to first- and second-generation EGFR-TKI therapy.

Citing Articles

The Role of Clinicopathological Features in Tyrosine Kinase Inhibitory Duration in EGFR Mutant Metastatic Non-Small Cell Lung Cancer.

Dogan E, Firat S, Cengiz M, Bozkurt O, Inanc M, Ozkan M J Clin Med. 2025; 14(4).

PMID: 40004680 PMC: 11857043. DOI: 10.3390/jcm14041149.

References

Planchard D, Janne P, Cheng Y, Yang J, Yanagitani N, Kim S . Osimertinib with or without Chemotherapy in -Mutated Advanced NSCLC. N Engl J Med. 2023; 389(21):1935-1948. DOI: 10.1056/NEJMoa2306434. View

Cross D, Ashton S, Ghiorghiu S, Eberlein C, Nebhan C, Spitzler P . AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014; 4(9):1046-61. PMC: 4315625. DOI: 10.1158/2159-8290.CD-14-0337. View

Shi Y, Au J, Thongprasert S, Srinivasan S, Tsai C, Khoa M . A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014; 9(2):154-62. PMC: 4132036. DOI: 10.1097/JTO.0000000000000033. View

Huang Y, Tseng J, Hsu K, Chen K, Su K, Yu S . The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M. Sci Rep. 2021; 11(1):12084. PMC: 8187359. DOI: 10.1038/s41598-021-91657-7. View

Yu H, Arcila M, Rekhtman N, Sima C, Zakowski M, Pao W . Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013; 19(8):2240-7. PMC: 3630270. DOI: 10.1158/1078-0432.CCR-12-2246. View

de Marinis F, Wu Y, de Castro Jr G, Chang G, Chen Y, Cho B . ASTRIS: a global real-world study of osimertinib in >3000 patients with T790M positive non-small-cell lung cancer. Future Oncol. 2019; 15(26):3003-3014. DOI: 10.2217/fon-2019-0324. View

Soria J, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee K . Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 378(2):113-125. DOI: 10.1056/NEJMoa1713137. View

Li Y, Lv X, Wang B, Xu Z, Wang Y, Sun M . Predicting EGFR T790M Mutation in Brain Metastases Using Multisequence MRI-Based Radiomics Signature. Acad Radiol. 2022; 30(9):1887-1895. DOI: 10.1016/j.acra.2022.12.030. View

Cho B, Lu S, Felip E, Spira A, Girard N, Lee J . Amivantamab plus Lazertinib in Previously Untreated -Mutated Advanced NSCLC. N Engl J Med. 2024; 391(16):1486-1498. DOI: 10.1056/NEJMoa2403614. View

10.

Li Y, Lv X, Wang Y, Xu Z, Lv Y, Hou D . CT-based nomogram for early identification of T790M resistance in metastatic non-small cell lung cancer before first-line epidermal growth factor receptor-tyrosine kinase inhibitors therapy. Eur Radiol Exp. 2023; 7(1):64. PMC: 10620367. DOI: 10.1186/s41747-023-00380-7. View

11.

Kim T, Jang T, Choi C, Kim M, Yong Lee S, Chang Y . Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non-Small Cell Lung Cancer: Updated Analysis of the RESET Study. Cancer Res Treat. 2023; 55(4):1152-1170. PMC: 10582551. DOI: 10.4143/crt.2023.493. View

12.

Lynch T, Bell D, Sordella R, Gurubhagavatula S, Okimoto R, Brannigan B . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350(21):2129-39. DOI: 10.1056/NEJMoa040938. View

13.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E . Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3):239-46. DOI: 10.1016/S1470-2045(11)70393-X. View

14.

Hochmair M, Morabito A, Hao D, Yang C, Soo R, Yang J . Sequential afatinib and osimertinib in patients with mutation-positive non-small-cell lung cancer: final analysis of the GioTag study. Future Oncol. 2020; 16(34):2799-2808. DOI: 10.2217/fon-2020-0740. View

15.

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

16.

Chiang C, Huang H, Shen C, Luo Y, Chen Y, Chiu C . Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI. Target Oncol. 2020; 15(4):503-512. DOI: 10.1007/s11523-020-00737-7. View

17.

Ninomaru T, Hata A, Kokan C, Okada H, Tomimatsu H, Ishida J . Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first/second generation EGFR-TKIs. Thorac Cancer. 2021; 12(6):746-751. PMC: 7952804. DOI: 10.1111/1759-7714.13822. View

18.

Ahn M, Tsai C, Shepherd F, Bazhenova L, Sequist L, Hida T . Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. Cancer. 2018; 125(6):892-901. DOI: 10.1002/cncr.31891. View

19.

Sequist L, Yang J, Yamamoto N, OByrne K, Hirsh V, Mok T . Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31(27):3327-34. DOI: 10.1200/JCO.2012.44.2806. View

20.

Ramalingam S, Vansteenkiste J, Planchard D, Cho B, Gray J, Ohe Y . Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC. N Engl J Med. 2019; 382(1):41-50. DOI: 10.1056/NEJMoa1913662. View